Everything is a buy at some stage, but with $5k putting this on the rights issue, one could ask what rights, nothing to say it would not trade under the issue Cheers Phil.
OAR Chris Judd's Talk Ya Book: Orthocell building on 'enormous potential' with steady growth - and US push to come
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025